Osteogenesis Imperfecta: characterization of fractures during pregnancy and post-partum.


Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
28 01 2022
Historique:
received: 16 05 2021
accepted: 06 12 2021
entrez: 29 1 2022
pubmed: 30 1 2022
medline: 12 3 2022
Statut: epublish

Résumé

Pregnancy and breastfeeding are associated with bone density loss. Fracture occurrence during pregnancy and post-partum, and its determinants, remain poorly known in Osteogenesis Imperfecta (OI). The aim of this study was to characterize fractures that occurred during pregnancy and post-partum in OI patients. We conducted a retrospective multicentric study including a total of 50 previously pregnant OI women from 10 Bone Centers in France. Among these patients, 12 (24%) patients experienced fractures during pregnancy or in the 6 months following delivery, and 38 (76%) did not experience any fracture. The most frequent localizations were: proximal femur (25%), spine (25%), distal femur (12.5%), and pelvis (12.5%). Fractures during pregnancy occurred during the third trimester and post-partum fractures occurred with a mean delay of 2 months following delivery. No fractures occurred during childbirth. We next compared the 12 patients with pregnancy or post-partum fractures with the 38 patients without fractures. Mean age at pregnancy was 32.7 ± 3.1 years-old in the fractured group, vs 29.3 ± 5.0 years-old in the non-fractured group (p = 0.002). Breastfeeding was reported in 85.7% of patients in the fractured group, vs 47.1% in the non-fractured group (p = 0.03). All patients with post-partum fractures were breastfeeding. Bone mineral density was significantly lower in patients with pregnancy-related fractures compared with other patients: spine Z-score - 2.9 ± 1.6DS vs - 1.5 ± 1.7DS (p = 0.03), and total hip Z-score - 2.0 ± 0.7DS vs - 0.5 ± 1.4DS (p = 0.04). At least one osteoporosis-inducing risk factor or disease other than OI was identified in 81.8% vs 58.6% of fractured vs non-fractured patients (not significant). Fracture during pregnancy or post-partum was not associated with the severity of OI. Bisphosphonates before pregnancy were reported in 16.7% and 21.1% of patients with pregnancy-related fractures and non-fractured patients, respectively (not significant). OI management during pregnancy and post-partum should aim for optimal control of modifiable osteoporosis risk factors, particularly in patients with low BMD. Breastfeeding should be avoided.

Sections du résumé

BACKGROUND
Pregnancy and breastfeeding are associated with bone density loss. Fracture occurrence during pregnancy and post-partum, and its determinants, remain poorly known in Osteogenesis Imperfecta (OI). The aim of this study was to characterize fractures that occurred during pregnancy and post-partum in OI patients.
RESULTS
We conducted a retrospective multicentric study including a total of 50 previously pregnant OI women from 10 Bone Centers in France. Among these patients, 12 (24%) patients experienced fractures during pregnancy or in the 6 months following delivery, and 38 (76%) did not experience any fracture. The most frequent localizations were: proximal femur (25%), spine (25%), distal femur (12.5%), and pelvis (12.5%). Fractures during pregnancy occurred during the third trimester and post-partum fractures occurred with a mean delay of 2 months following delivery. No fractures occurred during childbirth. We next compared the 12 patients with pregnancy or post-partum fractures with the 38 patients without fractures. Mean age at pregnancy was 32.7 ± 3.1 years-old in the fractured group, vs 29.3 ± 5.0 years-old in the non-fractured group (p = 0.002). Breastfeeding was reported in 85.7% of patients in the fractured group, vs 47.1% in the non-fractured group (p = 0.03). All patients with post-partum fractures were breastfeeding. Bone mineral density was significantly lower in patients with pregnancy-related fractures compared with other patients: spine Z-score - 2.9 ± 1.6DS vs - 1.5 ± 1.7DS (p = 0.03), and total hip Z-score - 2.0 ± 0.7DS vs - 0.5 ± 1.4DS (p = 0.04). At least one osteoporosis-inducing risk factor or disease other than OI was identified in 81.8% vs 58.6% of fractured vs non-fractured patients (not significant). Fracture during pregnancy or post-partum was not associated with the severity of OI. Bisphosphonates before pregnancy were reported in 16.7% and 21.1% of patients with pregnancy-related fractures and non-fractured patients, respectively (not significant).
CONCLUSIONS
OI management during pregnancy and post-partum should aim for optimal control of modifiable osteoporosis risk factors, particularly in patients with low BMD. Breastfeeding should be avoided.

Identifiants

pubmed: 35090500
doi: 10.1186/s13023-021-02148-x
pii: 10.1186/s13023-021-02148-x
pmc: PMC8796450
doi:

Substances chimiques

Bone Density Conservation Agents 0
Diphosphonates 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

22

Informations de copyright

© 2022. The Author(s).

Références

Osteoporos Int. 2012 Apr;23(4):1213-23
pubmed: 21607805
J Med Genet. 1979 Apr;16(2):101-16
pubmed: 458828
Am J Med Genet A. 2019 Dec;179(12):2393-2419
pubmed: 31633310
Calcif Tissue Int. 2021 Feb 23;:
pubmed: 33620518
Bone. 2004 Mar;34(3):570-8
pubmed: 15003805
Curr Opin Pediatr. 2014 Aug;26(4):500-7
pubmed: 25007323
Osteoporos Int. 2017 Nov;28(11):3135-3142
pubmed: 28879474
Lancet. 2004 Apr 24;363(9418):1377-85
pubmed: 15110498
J Med Genet. 2013 Jan;50(1):21-4
pubmed: 23240094
J Pediatr. 1982 Nov;101(5):767-70
pubmed: 6982323
Curr Opin Endocrinol Diabetes Obes. 2014 Dec;21(6):468-75
pubmed: 25191853
Hum Mol Genet. 2009 Feb 1;18(3):463-71
pubmed: 18996919
Am J Clin Nutr. 1987 Aug;46(2):319-23
pubmed: 3618535
Physiol Rev. 2016 Apr;96(2):449-547
pubmed: 26887676
J Perinatol. 2016 Oct;36(10):828-31
pubmed: 27442154
Curr Osteoporos Rep. 2007 Sep;5(3):91-7
pubmed: 17925189
Endocr Rev. 1997 Dec;18(6):832-72
pubmed: 9408745
J Obstet Gynaecol. 2002 Mar;22(2):169-72
pubmed: 12521699
J Matern Fetal Neonatal Med. 2016;29(14):2358-62
pubmed: 26372357
J Bone Miner Res. 1996 Aug;11(8):1052-60
pubmed: 8854240
Lancet. 2016 Apr 16;387(10028):1657-71
pubmed: 26542481
J Bone Miner Res. 2016 Dec;31(12):2159-2166
pubmed: 27345018
Osteoporos Int. 2019 May;30(5):939-948
pubmed: 30671611

Auteurs

Eugénie Koumakis (E)

Rheumatology Department, Cochin Hospital, Paris, AP-HP Centre-Paris University, Reference Center for Rare Genetic Bone Disorders-Cochin-constitutive site, Cochin Hospital, 27 Rue du Faubourg Saint-Jacques, 75014, Paris, France. eugenie.koumakis@aphp.fr.
Clinical Genetics, Reference Center for bone disorders, INSERM UMR 1163, Imagine Institute, Necker Enfants-Malades Hospital, AP-HP, Paris University, Paris, France. eugenie.koumakis@aphp.fr.

Valérie Cormier-Daire (V)

Clinical Genetics, Reference Center for bone disorders, INSERM UMR 1163, Imagine Institute, Necker Enfants-Malades Hospital, AP-HP, Paris University, Paris, France.

Azeddine Dellal (A)

Rheumatology Department, Cochin Hospital, Paris, AP-HP Centre-Paris University, Reference Center for Rare Genetic Bone Disorders-Cochin-constitutive site, Cochin Hospital, 27 Rue du Faubourg Saint-Jacques, 75014, Paris, France.

Marc Debernardi (M)

Rheumatology Department, Cochin Hospital, Paris, AP-HP Centre-Paris University, Reference Center for Rare Genetic Bone Disorders-Cochin-constitutive site, Cochin Hospital, 27 Rue du Faubourg Saint-Jacques, 75014, Paris, France.

Bernard Cortet (B)

Department of Rheumatology and ULR 4490 (MABLAB), Competence Center for Rare Genetic Bone Disorders, University-Hospital of Lille, 59000, Lille, France.

Françoise Debiais (F)

Department of Rheumatology, CHU Poitiers; CNRS ERL7003, University of Poitiers, Poitiers, France.

Rose-Marie Javier (RM)

Rheumatology Department, Competence Center for Rare Genetic Bone Disorders, University-Hospital of Strasbourg, 67098, Strasbourg, France.

Thierry Thomas (T)

Department of Rheumatology, CHU Saint-Etienne, INSERM U1059, Université de Lyon, Saint-Etienne, France.

Nadia Mehsen-Cetre (N)

Service de Rhumatologie, Centre de Compétence MOC et Dysplasie Fibreuse, CHU Bordeaux-Tripode, Bordeaux, France.

Martine Cohen-Solal (M)

Biocar Inserm U1132 and Université de Paris, Hôpital Lariboisière, 75010, Paris, France.

Elisabeth Fontanges (E)

Department of Rheumatology, Hôpital Edouard Herriot, CHU de Lyon, Lyon, France.

Michel Laroche (M)

Centre de Rhumatologie, CHU Purpan, 1 place du Dr Baylac, 31059, Toulouse Cedex, France.

Valérie Porquet-Bordes (V)

Endocrine, Bone Diseases, and Genetics Unit, Reference Centre for Rare Diseases of the Calcium and Phosphate Metabolism, ERN BOND, OSCAR Network, Children's Hospital, Toulouse University Hospital, Toulouse, France.

Christian Marcelli (C)

Department of Rheumatology, CHU Caen, Caen, France.

Alexandra Benachi (A)

Departement of Obstetrics, Gynecology and Reproductive Medicine, Hôpital Antoine-Béclère - Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France.

Karine Briot (K)

Rheumatology Department, Cochin Hospital, Paris, AP-HP Centre-Paris University, Reference Center for Rare Genetic Bone Disorders-Cochin-constitutive site, Cochin Hospital, 27 Rue du Faubourg Saint-Jacques, 75014, Paris, France.
INSERM UMR 1153, INSERM, PRESS Sorbonne Paris-Cité, Paris, France.

Christian Roux (C)

Rheumatology Department, Cochin Hospital, Paris, AP-HP Centre-Paris University, Reference Center for Rare Genetic Bone Disorders-Cochin-constitutive site, Cochin Hospital, 27 Rue du Faubourg Saint-Jacques, 75014, Paris, France.
INSERM UMR 1153, INSERM, PRESS Sorbonne Paris-Cité, Paris, France.

Catherine Cormier (C)

Rheumatology Department, Cochin Hospital, Paris, AP-HP Centre-Paris University, Reference Center for Rare Genetic Bone Disorders-Cochin-constitutive site, Cochin Hospital, 27 Rue du Faubourg Saint-Jacques, 75014, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH